The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy First and only prefilled syringe treatment option FDA-approved to ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the ...

The European Medicines Agency (EMA) has approved the pre-filled syringe for the administration of Eylea 8 mg (114.3 mg/ml solution for injection) in the European Union. The new pre-filled syringe ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), ...

(RTTNews) - Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar ...

Syringe marking errors, which can lead to incorrect dosing, caused a recall of Enoxaparin Sodium Injection, a generic version of blood clot medication Lovenox. The recall issued Tuesday by Apotex, a ...

The MarketWatch News Department was not involved in the creation of this content.-- Omlyclo(TM) (omalizumab) is the first and only omalizumab biosimilar approved in Europe -- Omly ...